Business Wire

TX-FLUENCE

Share
Fluence Announces Major Presence at MJBizCon 2023, Including Panel of Industry-Leading Growers, Educational Series and Product Demos

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced it will have a major presence at MJBizCon, the leading cannabis industry conference. Fluence Cannabis Solutions Architect Casey Rivero will join a panel alongside Fluence customers to discuss how growers can maximize crop quality. In addition, the company is investing in connecting the cannabis community at this year’s conference, providing product demonstrations from Fluence’s line of leading LED lighting solutions as well as hosting a series of Grower Talks with Fluence experts at the company’s booth.

Moderated by MJBizDaily reporter Solomon Israel, Rivero’s session, entitled “Powering Through Market Conditions: How Growers in Established Markets are Doubling Down on Quality and Boosting Their Bottom-Line,” will provide growers with concrete steps they can take to navigate an uncertain market. Rivero, a former cannabis cultivator, will be joined by Travis Higginbotham, StateHouse vice president of cultivation; Chris Castle, COO and co-founder of Flora & Flame; Andrew Reich, division manager at SunMed Growers; and Tyler Smith, principal advisor at Smith Cultivations. The panel will take place from 10 to 10:40 a.m. PST on Thursday, Nov. 30 in room N259.

“Though I have had my own grows for years, I find myself learning every single day from the cultivators we collaborate with,” Rivero said. “I’m honored to sit beside some of the industry’s most successful and innovative growers and share our firsthand knowledge on what it takes to deliver the highest-quality product to the market.”

The company will also host a series of Grower Talks throughout the show at the Fluence booth (No. 43023). As part of the series, growers can learn about innovative HPS retrofitting strategies, intercanopy lighting solutions and other topics top of mind in the cannabis industry. Growers will have the opportunity to ask questions and solicit advice from experts in their field, including Taylor Kirk and Dr. Jason Matlock from Fluence's Horticulture Services division, as well as Dr. David Hawley, principal scientist and head of Fluence's Crop Research division. For a detailed list of sessions, including times and featured experts, visit Fluence’s social media the week of the show.

“MJBizCon is an opportunity for the brightest minds in cannabis to come together and share the latest innovations across every facet of the industry,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re looking forward to amplifying the voices of our customers as well as sharing insights from our in-house cannabis experts to showcase how Fluence’s LED technology can help cultivators grow smarter, more efficiently and at the highest quality.”

Fluence experts will also demo products from the company’s suite of LED technologies, including its RAPTR, VYPR, SPYDR, RAZR and VYNE fixtures—each designed to make cannabis growers’ lives easier. According to Fluence and Cannabis Business Times’ recently released “State of the Cannabis Lighting Market” report, growers are addressing ongoing industry challenges by redoubling their focus on crop quality. Fluence’s LED technology and cultivation expertise helps cannabis growers throughout the world improve bud density and quality and drive financial success.

For more information on Fluence, stop by the company’s MJBizCon booth in Las Vegas, No. 43023, between Nov. 28 and Dec. 1—or visit www.fluence-led.com.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence-led.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116207472/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye